A Phase 1, Open-Label, Randomized, Single-Dose, 2-Cohort, 3-Way Crossover Study To Determine Bioequivalence Of 4 Mg And 8 Mg Fesoterodine SR Tablet Of Commercial Formulation And 8 Mg Fesoterodine SR Tablet Between Formulation E(1) And Formulation F And Investigate Food Effect On Commercial Formulation In Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2009
At a glance
- Drugs Fesoterodine (Primary)
- Indications Overactive bladder
- Focus Pharmacokinetics; Registrational
- Sponsors Pfizer
- 25 Jun 2009 Actual initiation date changed from Dec 2008 to Oct 2008 as reported by ClinicalTrials.gov.
- 25 Jun 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 16 Dec 2008 New trial record.